Cambridge Major Laboratories (CML) is expanding its large scale API manufacturing facility in Germantown, WI. The expansion will include additional reactor capacity as well as isolation equipment. CML has also made investments in engineering controls to ensure the sustainability of the business.
“We are very pleased to report that our faith in the ‘invest in the West’ policy initiated a few years ago continues to bear fruit,” said Brian Scanlan, CML’s president and chief executive officer. “CML is very well positioned to support both increasing demand for our commercial products as well as our healthy pipeline of APIs in later phases of clinical development. By making these new investments, we show our commitment to support our loyal client base at the most critical point, when quality and timely delivery are imperative.”